Tens of billions of euros are invested globally in pharmaceutical research each year, yet only a limited number of new drugs ever reach the market. This immense bottleneck is being challenged by the emergence of agentic artificial intelligence, spearheaded by a collaboration between IQVIA—the world’s leading provider of clinical research and healthcare intelligence—and NVIDIA. The partnership was announced at NVIDIA GTC Paris during VivaTech, highlighting IQVIA’s deployment of artificial intelligence orchestrator agents, engineered with NVIDIA´s technology, to streamline and accelerate the intricate processes involved in pharmaceutical development for thousands of global clients.
These orchestrator agents operate as supervisors, directing specialized sub-agents that tackle discrete tasks such as speech-to-text transcription, clinical coding, structured data extraction, and data summarization. The modularity of this system allows expert human oversight while maximizing workflow speed. IQVIA leverages its vast databases—spanning many petabytes—and deep domain expertise to train and fine-tune these models, optimizing both productivity and precision across clinical workflows. The deployment of these agents on IQVIA’s healthcare-grade artificial intelligence platform is designed to impact every stage of the pharmaceutical lifecycle, with a particular focus on expediting clinical trials.
Clinical trial start-up, a historically lengthy and manual process often spanning 200 days, benefits from orchestrator agents that automate and accelerate early phases, notably in target identification and clinical data review. The target identification agent synthesizes research and biomedical data to uncover emergent scientific areas for prioritization and drug repurposing, unlocking opportunities that were previously out of reach. Elsewhere, the clinical data review agent rapidly flags issues, shrinking review timelines from seven weeks to just two. This orchestration is powered by NVIDIA’s NIM microservices, part of the AI Enterprise software platform, enabling autonomous, phased problem-solving and allowing research teams to concentrate on critical decision-making rather than administrative burdens.
The advantages extend well beyond clinical trials. Post-market, IQVIA’s orchestrator agents support pharmaceutical companies as they navigate complex market dynamics, optimize the path to patients, and identify bottlenecks in drug accessibility by analyzing patient records, prescriptions, and laboratory results in a fraction of previous timelines. Field companion orchestrator agents personalize insights for pharmaceutical sales teams, integrating physician demographics, prescribing patterns, and digital behavior to inform highly tailored, data-driven engagements with healthcare professionals. According to Avinob Roy, IQVIA´s vice president and general manager of commercial analytics solutions, the collective capabilities of these artificial intelligence agents aim to transform operational efficiency, precision, and outcomes for both healthcare professionals and patients throughout the life sciences sector.
